NCT00251004 arm group 45a2fc76c792174cb5568c58e8cf1154 [clinicaltrials_resource:NCT00251004/arm-group/45a2fc76c792174cb5568c58e8cf1154]
Corticosteroids [clinicaltrials_resource:2e40285d72c4f72033b40fae9122b906]Basiliximab [clinicaltrials_resource:37bc4403f2e69d0422ececbfd595d37f]Everolimus [clinicaltrials_resource:518ccf2b9de10166e0ebc03587bd3ce2]Cyclosporine A (CsA) [clinicaltrials_resource:77e70ada8c4813da41ed1fd351511ce5]clinicaltrials:NCT00251004
arm group [clinicaltrials_vocabulary:arm-group]
NCT00251004 arm group 45a2fc76c792174cb5568c58e8cf1154 [clinicaltrials_resource:NCT00251004/arm-group/45a2fc76c792174cb5568c58e8cf1154]
Bio2RDF identifier
NCT00251004/arm-group/45a2fc76c792174cb5568c58e8cf1154
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a2fc76c792174cb5568c58e8cf1154
description [clinicaltrials_vocabulary:description]
1.5 mg everolimus (one 0.75-mg ...... ed according to local therapy.
identifier
clinicaltrials_resource:NCT00251004/arm-group/45a2fc76c792174cb5568c58e8cf1154
title
NCT00251004 arm group 45a2fc76c792174cb5568c58e8cf1154
@en
type
label
NCT00251004 arm group 45a2fc76 ...... 2fc76c792174cb5568c58e8cf1154]
@en